FindTrial
Sign In

Efficacy of Oral Tofacitinib in Combination of Narrow Band UVB in Treatment of Vitiligo

Efficacy of Oral Tofacitinib in Combination With Narrow Band UVB in the Treatment of Vitiligo

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07044141
Acronym
NB-UVB
Enrollment
20
Registered
2025-06-29
Start date
2025-03-01
Completion date
2025-09-30
Last updated
2025-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Brief summary

20 patients will be enrolled. All were given narrowband UVB . 10 wil be give oral azathriopfine . 10 will be given tofacitinib

Detailed description

Total 20 patients will be enrolled. All were given narrowband UVB . 10 wil be give oral azathriopfine 50mg twice daily. 10 will be given tofacitinib 5mg twice daily. For 6 months

Interventions

DRUGAzathioprine

azathioprine 50mg twice daily will be given

DRUGTofacitinib

It is a janus kinase inhibitor

Sponsors

Lahore General Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* patient of vitiligo with any VASI both genders 18 to 60yrs

Exclusion criteria

* pregnancy/lactation Hyerlipidrmia Patient on immunemodulator Histry pf tuberculosis Immunocompromised patients

Design outcomes

Primary

MeasureTime frameDescription
VASI improvement upto 50%6 monthsStudy will be considered efficacious if 50% improvement in VASI from baseline is seen by end of 6 months of study

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026